سه شنبه 7 مهر 1405
دوره 14، شماره 3 - ( 6-1405 )
جلد 14 شماره 3 صفحات 300-287 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hajialibeig A, Hosseinzadeh F, Kamali M, Navaeifar M R, Shahbaznejad L, Movahedi F S, et al . Ivermectin for Management of COVID-19 in Iranian Children: Results of Two Randomized, Placebo-controlled Clinical Trials. J. Pediatr. Rev 2026; 14 (3) :287-300
URL: http://jpr.mazums.ac.ir/article-1-804-fa.html
URL: http://jpr.mazums.ac.ir/article-1-804-fa.html
Ivermectin for Management of COVID-19 in Iranian Children: Results of Two Randomized, Placebo-controlled Clinical Trials. Journal of Pediatrics Review. 1405; 14 (3) :287-300
چکیده: (11 مشاهده)
Background: The global search for effective COVID-19 treatments extended to the use of ivermectin, a drug with potential antiviral properties. However, evidence remains conflicting, especially for children.
Objectives: This study aimed to investigate the efficacy and safety of ivermectin for treating COVID-19 in Iranian children through two independent randomized, placebo-controlled trials.
Methods: Two multicenter, randomized, double-blind, placebo-controlled clinical trials were conducted to evaluate the efficacy of ivermectin in 195 children with COVID-19, including 66 inpatients (35 in the ivermectin group and 31 in the placebo group) and 129 outpatients (70 in the ivermectin group and 59 in the placebo group). The treatment group received a daily oral dose of ivermectin (400 μg/kg/day, 6 mg tablet) for three consecutive days, while the control group received an identical placebo. The primary outcome was disease prognosis. The secondary outcomes for inpatients included duration of hospitalization, need for pediatric intensive care unit (PICU) admission, need for oxygen, adverse events, and mortality. For outpatients, secondary outcomes were need for hospitalization, need for PICU admission, viral clearance, adverse events, and mortality.
Results: All inpatients in both ivermectin and placebo groups fully recovered from COVID-19. Among outpatients, 98.6% recovered after ivermectin use, and 100% recovered with placebo. A significant difference was found in the need for PICU admission among inpatients (2.8% in the ivermectin group and 25.8% in the placebo group; P=0.010). Additionally, viral clearance differed significantly, with more patients in the ivermectin group testing negative for COVID-19 on day six than in the placebo group (P=0.042). The length of hospital stay was similar for both groups.
Conclusions: Although ivermectin can reduce the need for PICU admission among inpatient children with COVID-19, it did not improve overall clinical recovery or length of hospital stay. For outpatients, ivermectin does not enhance recovery or reduce the need for hospitalization but showed promising viral clearance effects. Considering all aspects, the use of ivermectin in the treatment of children with COVID-19 cannot be recommended.
Objectives: This study aimed to investigate the efficacy and safety of ivermectin for treating COVID-19 in Iranian children through two independent randomized, placebo-controlled trials.
Methods: Two multicenter, randomized, double-blind, placebo-controlled clinical trials were conducted to evaluate the efficacy of ivermectin in 195 children with COVID-19, including 66 inpatients (35 in the ivermectin group and 31 in the placebo group) and 129 outpatients (70 in the ivermectin group and 59 in the placebo group). The treatment group received a daily oral dose of ivermectin (400 μg/kg/day, 6 mg tablet) for three consecutive days, while the control group received an identical placebo. The primary outcome was disease prognosis. The secondary outcomes for inpatients included duration of hospitalization, need for pediatric intensive care unit (PICU) admission, need for oxygen, adverse events, and mortality. For outpatients, secondary outcomes were need for hospitalization, need for PICU admission, viral clearance, adverse events, and mortality.
Results: All inpatients in both ivermectin and placebo groups fully recovered from COVID-19. Among outpatients, 98.6% recovered after ivermectin use, and 100% recovered with placebo. A significant difference was found in the need for PICU admission among inpatients (2.8% in the ivermectin group and 25.8% in the placebo group; P=0.010). Additionally, viral clearance differed significantly, with more patients in the ivermectin group testing negative for COVID-19 on day six than in the placebo group (P=0.042). The length of hospital stay was similar for both groups.
Conclusions: Although ivermectin can reduce the need for PICU admission among inpatient children with COVID-19, it did not improve overall clinical recovery or length of hospital stay. For outpatients, ivermectin does not enhance recovery or reduce the need for hospitalization but showed promising viral clearance effects. Considering all aspects, the use of ivermectin in the treatment of children with COVID-19 cannot be recommended.
نوع مطالعه: Original Article |
دریافت: 1404/7/10 | پذیرش: 1405/6/28 | انتشار: 1405/6/28
دریافت: 1404/7/10 | پذیرش: 1405/6/28 | انتشار: 1405/6/28
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
